GSK issues statement to HGS shareholders

Friday 18 May 2012

GlaxoSmithKline Plc has told shareholders of Human Genome Sciences that its $13 per share cash offer represents “full and fair value” for the company. The tender will close on 7 June. The HGS board has recommended against the offer.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom